One size does not fit all: qual ...
Adjuvant endocrine therapy for breast cancer is associated with significant improvements in disease-related outcomes. Five years of tamoxifen therap ...
Disparities in breast cancer ch ...
Disparities in breast cancer stage and mortality by race/ethnicity in the United States are persistent and well known. However, few studies have ass ...
Spectrum of BRCA1/2 point mutat ...
The distribution of BRCA1/2 germline mutations in breast/ovarian cancer (BC/OC) families varies among different populations. In the Chilean populati ...
Lack of association between ATM ...
Epidemiological studies have evaluated the association between ATM C.1066-6T[G (IVS10-6T[G) mutation and breast cancer risk. However, the results re ...
Effect of aspirin and other NSA ...
Aspirin and other non-aspirin non-steroidal anti-inflammatory drugs (NSAIDs) can inhibit aromatase activity and thus could selectively lower inciden ...
Impact of treatment characteris ...
Pathological complete response (pCR) to neoadjuvant treatment correlates with outcome in breast cancer. We determined whether characteristics of neo ...
Anastrozole and letrozole: an i ...
Previous studies have demonstrated that both anastrozole and letrozole are well tolerated. Letrozole suppresses estrogen to a greater degree than an ...
Socioeconomic differences in su ...
There seem to be socioeconomically differences in survival for females with breast cancer, usually associated with a higher stage of disease. Howeve ...
Concurrent use of tamoxifen wit ...
Concurrent use of tamoxifen and cytochrome P450 2D6 (CYP2D6) inhibitors, such as selective serotonin reuptake inhibitors, has been shown to decrease ...
Evidence on the association bet ...
Several molecular epidemiological studies were conducted in recent years to evaluate the association between NQO1 Pro187Ser polymorphism and breast ...
Association between polymorphis ...
Epidemiological studies have evaluated the association between ataxia telangiectasia mutated (ATM) gene polymorphisms and breast cancer risk. Howeve ...
Phase I/II study of sorafenib w ...
We evaluated the use of sorafenib to overcome resistance to aromatase inhibitors (AIs) in patients with metastatic breast cancer who had disease rec ...
Disseminated tumor cells: the m ...
Bone marrow DTC in breast cancer It is a tenet of breast cancer biology that patients with primary (Stages I–III) breast cancer can harbor residual ...
The mammalian target of rapamyc ...
mTOR plays a key role in tumor cell cycle control, proliferation, and survival. RAD001 (everolimus) is a novel macrolide that inhibits mTOR and thus ...
Let-7a regulation of insulin-li ...
Expression of certain microRNA genes is regulated by DNA methylation, which in turn affects the activities of their downstream molecules. Our previo ...
Vascular endothelial growth fac ...
A cross talk between tyrosine kinase receptors and mitogen-activated protein kinases (MAPKs) is proposed as involved in endocrine resistance. We wan ...
Immunohistochemistry compared t ...
The purpose of this study is to compare immunohistochemistry (IHC) and cytosol-based assays for determination of estrogen receptor (ER) and predicti ...
Bilateral breast cancer: analys ...
There has been conflicting evidence on the impact of bilateral breast cancer (BBC) on the survival and management of patients. The objectives of thi ...
Benefits of early and prolonged ...
Response to fulvestrant and survival in postmenopausal hormone-sensitive advanced breast cancer was investigated within a non-randomized, In-Practic ...
Detection and clinical relevanc ...
The factors determining the clinical relevance of disseminated tumor cells (DTC) in breast cancer patients are largely unknown. Here we compared the ...
Clinical potential of the mTOR ...
The mammalian target of rapamycin (mTOR) and its substrates S6K1 and S6K2 regulate cell growth, proliferation, and metabolism through translational ...
Bone mineral density and risk o ...
To determine if higher bone mineral density (BMD) is a risk factor for breast cancer in women age 50 years and older. 37,860 women C50-year old with ...
Phase I trial of oral mTOR inhi ...
To determine the feasible dose and schedule for everolimus, an oral mTOR inhibitor, combined with vinorelbine and trastuzumab for patients with HER2 ...
A gene expression signature ide ...
Prognosis of basal breast cancers is poor but heterogeneous. Medullary breast cancers (MBC) display a basal profile, but a favorable prognosis. We h ...
Oncologic safety of breast cons ...
The objective of this study is to analyse local recurrence rates in patients receiving neoadjuvant chemotherapy (nCT) comparing mastecomized (MX) pa ...